00:15 , Mar 9, 2019 |  BC Extra  |  Clinical News

Jounce seeking tumor-agnostic approach for ICOS agonist

Jounce said the ICOS hi CD4 T cells biomarker could allow the company to take a tumor-agnostic approach for its ICOS agonist vopratelimab (JTX-2011) to select patient populations more likely to respond to the therapy....
00:27 , Mar 8, 2019 |  BC Innovations  |  Targets & Mechanisms

Flipping the switch in immuno-oncology

Tumor myeloid cells are emerging as prime candidates for filling a hole in the immuno-oncology tool box, offering targets that can simultaneously release the brakes and rev up the gas in the immune system. As...
22:34 , Mar 7, 2019 |  BC Extra  |  Preclinical News

Beyond cancer: CAR T cells treat lupus in mice

University of Tennessee researchers have shown that CD19-targeted CAR T cells could help treat lupus, suggesting the approach could be applied to diseases beyond cancer. Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by...
19:11 , Mar 4, 2019 |  BC Innovations  |  Distillery Therapeutics

gp120-binding bNAbs for HIV

DISEASE CATEGORY: Infectious disease INDICATION: HIV/AIDS Cell culture studies suggest broadly neutralizing antibodies (bNAbs) that bind two adjacent HIV gp120 monomers in HIV env could help prevent and treat HIV-1 infection. The bNAbs were generated...
23:22 , Feb 20, 2019 |  BC Innovations  |  Distillery Therapeutics

Autoimmune disease

INDICATION: Multiple sclerosis (MS) Mouse studies suggest inhibiting DGAT1 could help treat MS. In the experimental autoimmune encephalomyelitis (EAE) mouse model of MS, levels of DGAT1 were higher in CD4 + T cells from the...
14:01 , Jan 3, 2019 |  BC Innovations  |  Translation in Brief

Neo opportunities in glioblastoma

Phase I results from a consortium led by BioNTech AG and Immatics Biotechnologies GmbH convinced both companies that personalized immunotherapies can turn on T cell activity in glioblastoma, an immunologically "cold" cancer. The study is...
18:56 , Dec 13, 2018 |  BC Innovations  |  Translation in Brief

3-D immune response

A Boston Children's Hospital team has developed a 3-D human tissue model that reproduces age-specific immune responses to vaccine antigens and could surmount the hurdles of developing vaccines for neonates and infants. Preclinical vaccine development...
17:51 , Dec 7, 2018 |  BC Week In Review  |  Clinical News

New BCMA-targeted therapies could help sicker patients

Oral abstracts at this year’s American Society of Hematology meeting describing next generation anti-BCMA CARs from Poseida Therapeutics Inc. and Fred Hutchinson Cancer Research Center and a bispecific antibody from Amgen Inc. (NASDAQ:AMGN) hint that...
17:31 , Dec 7, 2018 |  BC Week In Review  |  Clinical News

Celgene reports updated ORR of 82% for anti-BCMA CAR T therapy in MM

The Juno Therapeutics Inc. subsidiary of Celgene Corp. (NASDAQ:CELG) reported updated data from the Phase I/II EVOLVE trial to treat relapsed and/or refractory multiple myeloma in patients who have received at least three prior regimens...
01:23 , Dec 7, 2018 |  BC Week In Review  |  Financial News

Panacea backs Tactiva in $35M series A

Cancer immunotherapy company Tactiva Therapeutics Inc. (Buffalo, N.Y.) announced Dec. 3 it raised $18 million in the first tranche of a $35 million series A round led by Chinese VC firm Panacea Ventures. VI Ventures...